Sernova to Present Company and Clinical Update at Biotech Showcase(TM) San Francisco

LONDON, ONTARIO--(Marketwire - Jan. 9, 2012) - Sernova Corp. (TSX VENTURE:SVA), today announced that Dr. Philip Toleikis, Ph.D., President and CEO of Sernova, will present an update on the company's technology and its plans to initiate patient enrollment in a Phase I/II clinical trial for its Cell Pouch™ System at 11 a.m. PST, Monday, Jan. 9, at the Biotech Showcase™. The conference will be held at Parc 55 Wyndham Union Square Hotel in San Francisco.

Based on positive preclinical results, Sernova is preparing for the initiation of human clinical studies where patients with diabetes will be implanted with the Cell Pouch™ followed by transplantation of donor islets. The Cell Pouch™ has been designated as a medical device for regulatory purposes and Dr. James Shapiro (University of Alberta, Edmonton) developer of the Edmonton Protocol will be the principal clinical investigator for the diabetes study.

About the Biotech Showcase™ (Innovation -Opportunity - Collaboration):

Now in its fourth year, Biotech Showcase™ will feature corporate presentations by 200+ innovative life science companies to an audience of public and private investors, business development executives and professional advisors who are interested in investment opportunities and collaboration. Biotech Showcase was co-founded by Demy-Colton Life Science Advisors and EBD Group, two organizations that have a long and successful history building programs that meet the needs of the life sciences industry. Visit our website for more information: www.ebdgroup.com/bts.

About Sernova

Sernova Corp. is a Canadian-based health sciences company focused on product development and commercialization of innovative proprietary platform medical technologies in the cell therapy arena such as the Cell Pouch System™ to provide a safe and efficacious environment for therapeutic cells and Sertolin™, a technology which, when combined with cell therapy, may protect therapeutic cells without the need for patients to take anti-rejection drugs. Sernova's first cell therapy application is for insulin-dependent diabetes to reduce or eliminate the need for insulin injections.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities -- that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.